These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18410043)

  • 41. Identification of an extraneous black particle in a glass syringe: extractables/leachables case study.
    Nashed-Samuel Y; Torraca G; Liu D; Fujimori K; Zhang Z; Wen ZQ; Lee H
    PDA J Pharm Sci Technol; 2010; 64(3):242-8. PubMed ID: 21502024
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex.
    Deechongkit S; Aoki KH; Park SS; Kerwin BA
    J Pharm Sci; 2006 Sep; 95(9):1931-43. PubMed ID: 16850392
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low Leachable Container System Consisting of a Polymer-Based Syringe with Chlorinated Isoprene Isobutene Rubber Plunger Stopper.
    Kiminami H; Takeuchi K; Nakamura K; Abe Y; Lauwers P; Dierick W; Yoshino K; Suzuki S
    PDA J Pharm Sci Technol; 2015; 69(6):713-24. PubMed ID: 26659102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study.
    Verhelst D; Rossert J; Casadevall N; Krüger A; Eckardt KU; Macdougall IC
    Lancet; 2004 May; 363(9423):1768-71. PubMed ID: 15172775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of UV-absorbing extractables from rubber closures used in containers of injectable powder and safety assessment of leachables in the drug.
    Wei Y; Wu Y; Zhu T; Li Z; Zhang Y
    J Pharm Biomed Anal; 2017 May; 138():256-266. PubMed ID: 28231528
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lesson learned from Eprex-associated pure red cell aplasia.
    Schellekens H
    Kidney Blood Press Res; 2007; 30 Suppl 1():9-12. PubMed ID: 17726337
    [No Abstract]   [Full Text] [Related]  

  • 47. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.
    Evens AM; Bennett CL; Luminari S
    Best Pract Res Clin Haematol; 2005; 18(3):481-9. PubMed ID: 15792923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin].
    Grzegorzewska AE; Sucharzewska-Tomczak M
    Pol Merkur Lekarski; 2004 Oct; 17(100):407-9. PubMed ID: 15690716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategy for identification of leachables in packaged pharmaceutical liquid formulations.
    Pan C; Harmon F; Toscano K; Liu F; Vivilecchia R
    J Pharm Biomed Anal; 2008 Feb; 46(3):520-7. PubMed ID: 18180126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extractables and leachables considerations for prefilled syringes.
    Jenke DR
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1591-600. PubMed ID: 24955780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pure red cell aplasia due to follow-on epoetin.
    Keithi-Reddy SR; Kandasamy S; Singh AK
    Kidney Int; 2008 Dec; 74(12):1617-22. PubMed ID: 18547998
    [No Abstract]   [Full Text] [Related]  

  • 52. Erythropoietin-Associated PRCA: Still an Unsolved Mystery.
    Schellekens H; Jiskoot W
    J Immunotoxicol; 2006 Sep; 3(3):123-30. PubMed ID: 18958692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pure red cell aplasia induced by erythropoiesis-stimulating agents.
    Pollock C; Johnson DW; Hörl WH; Rossert J; Casadevall N; Schellekens H; Delage R; De Francisco A; Macdougall I; Thorpe R; Toffelmire E
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):193-9. PubMed ID: 18178785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin.
    Howman R; Kulkarni H
    Nephrol Dial Transplant; 2007 May; 22(5):1462-4. PubMed ID: 17314208
    [No Abstract]   [Full Text] [Related]  

  • 55. Pure red-cell aplasia and recombinant erythropoietin.
    Gershon SK; Luksenburg H; Coté TR; Braun MM
    N Engl J Med; 2002 May; 346(20):1584-6; author reply 1584-6. PubMed ID: 12015400
    [No Abstract]   [Full Text] [Related]  

  • 56. Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?
    Macdougall IC
    Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii18-21. PubMed ID: 16079325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
    Casadevall N; Nataf J; Viron B; Kolta A; Kiladjian JJ; Martin-Dupont P; Michaud P; Papo T; Ugo V; Teyssandier I; Varet B; Mayeux P
    N Engl J Med; 2002 Feb; 346(7):469-75. PubMed ID: 11844847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to "a case study using Epoetin Alfa from Epogen and EPREX".
    Heavner GA; Arakawa T; Philo JS; Calmann MA; Labrenz S
    J Pharm Sci; 2007 Dec; 96(12):3214-25. PubMed ID: 17721976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of extractables by liquid chromatography-high resolution mass spectrometry: A case study to understand the extraction profile of different disposable syringes.
    Kurmi M; Prasad S; Panduranga NS; Jayaraman K; Bhutani H
    J Pharm Biomed Anal; 2020 Nov; 191():113602. PubMed ID: 33010603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leachable diphenylguanidine from rubber closures used in pre-filled syringes: A case study to understand solid and solution interactions with oxytocin.
    Zidan AS; Aqueel SM; Alayoubi A; Mohammad A; Zhang J; Rahman Z; Faustino P; Lostritto RT; Ashraf M
    Int J Pharm; 2017 Oct; 532(1):491-501. PubMed ID: 28935251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.